Polyoxyethylene monostearate (PMG) veterinary grade is a nonionic amphiphilic pharmaceutical ingredient supplied as a waxy solid, flake, or pastille for incorporation into tablets, injections, capsules, powders, granules, premixes, and solutions. The substance is identified by CAS Number 9004-99-3 and belongs to the polyoxyl stearate family, in which a saturated C18 fatty acid is bonded to a hydrophilic polyoxyethylene chain. Representative model designations encode the nominal average number of ethylene oxide repeat units: PMG-6, PMG-8, PMG-20, PMG-40, and PMG-100. The 40-mole ethoxylate combines a hydrophilic-lipophilic balance of approximately 16.9 with a melting/solidification interval of 38–46 °C and a waxy solid form; PMG-8 has an HLB near 11.1 and is oil-dispersible rather than water-soluble, while PMG-100 is more hydrophilic but softer and more hygroscopic. The product is a controlled mixture of ethylene oxide homologues and mono-/di-ester components rather than a single molecular species. Monoester content, free polyethylene glycol content, and ethylene oxide chain distribution influence surface activity, gelling behaviour, and melt viscosity.

The limits are representative monograph-based values for the 40-mole ethoxylate. Lower ethoxylates show lower saponification and hydroxyl values because of reduced polyoxyethylene content; higher ethoxylates yield softer masses and greater hygroscopicity. Additional batch release tests include iodine value NMT 2 g I₂/100 g, free glycerol NMT 1.0%, and a manufacturer-specific peroxide value. The iodine value differentiates PMG from oleate-based surfactants such as polysorbate 80, which has an unsaturated C18:1 tail and a higher iodine value. Acid value and saponification value are trended as indicators of ester integrity. Manufacturing under current good manufacturing practice is expected; residual solvent and elemental impurity assessments follow ICH Q3C and ICH Q3D, while veterinary submissions in VICH regions use VICH GL18 and VICH GL39. Certificates of origin should state whether the stearic acid fraction is vegetable-derived or animal-derived to support TSE/BSE risk assessment.

What Limits Parenteral Use of PMG in Multi-Species Injectable Formulations?

Parenteral formulations containing PMG are constrained by peroxide potential, bacterial endotoxin burden, and particulate count after terminal sterilization. The saturated C18 stearate chain reduces autoxidation compared with polysorbate 80, but the polyoxyethylene portion can still generate peroxides during high-temperature exposure. Injectable-grade material is handled under nitrogen and stored in sealed polyethylene-lined drums; a manufacturer-specific peroxide value is commonly set at NMT 5 mEq/kg because basic monographs may not include this parameter. Bacterial endotoxin limits are based on the intended dose and species and are determined by Ph. Eur. 2.6.14; intravenous products are assessed for subvisible particulates by USP <788>. Dry-heat depyrogenation at 250 °C is not feasible because PMG degrades above approximately 70 °C; terminal filtration of a warm aqueous solution through a 0.22 µm sterilizing-grade filter is preferred. Autoclaving at 121 °C for 15 minutes can accelerate ester hydrolysis if the aqueous phase is buffered outside 5.0–6.5; nitrogen overlay and absence of strong oxidizers are standard. For companion-animal parenteral products, hemocompatibility testing according to ISO 10993-4 is appropriate. Published stability data for dilute PMG solutions in polyolefin containers is limited, so pilot-scale confirmation is required before commercial scale-up.

Tablet and capsule manufacture uses PMG as a thermoplastic binder, melt-granulation agent, or wetting agent for poorly soluble veterinary actives. Concentrations of 0.5–3.0% w/w are typical for wetting in immediate-release tablets; higher levels of 5–15% w/w create lipid-matrix systems that modulate release. Disintegration and dissolution are assessed by USP <701> and USP <711> in purified water at 37 ± 2 °C; dissolution vessels with USP Apparatus 2 paddles at 50 rpm are used for routine batch testing. On rotary tablet presses with D-tooling, PMG at 2% w/w can modify die-wall friction and ejection force; compression and ejection profiles are monitored using instrumented tooling, and tablet breaking force is tested according to USP <1217>. In semi-solid capsule filling, PMG-40 is combined with medium-chain triglycerides or glyceryl esters and filled at 40–50 °C through a thermostatted hopper; cooling tunnels at 15–20 °C prevent gelatin shell deformation. Stability of PMG-containing tablets under accelerated conditions of 40 °C and 75% relative humidity requires HDPE packaging with desiccant; moisture uptake above 60% relative humidity can raise water content and alter matrix release.

Powders, granules, and medicated feed premixes require PMG to be converted into a free-flowing adsorbed form. The material is adsorbed onto colloidal silicon dioxide, calcium silicate, or pregelatinized starch at PMG-to-carrier ratios of 1:1 to 1:3 by blending at 25–40 °C. If ambient relative humidity exceeds 60%, pre-drying at 40–45 °C in a forced-air oven until water content is below 3.0% prevents agglomeration during milling. Blend uniformity is assessed by sampling 10 locations with an acceptance criterion of RSD not more than 5.0%; powder flow is evaluated by USP <1174>. In pelleted feed premixes, steam conditioning at 70–80 °C may soften PMG and assist binder function, but die clogging can occur when PMG exceeds 15% w/w of the premix. Granule size distribution is monitored with sieves from 125 µm to 1000 µm; the water-soluble fraction of PMG-40 releases from the carrier in aqueous feed slurries without high-shear mixing.

Hot-Melt Extrusion and High-Shear Wet-Granulation Processing Windows

Hot-melt extrusion with twin-screw equipment having length-to-diameter ratios of 25:1 to 40:1 requires a narrow barrel-temperature corridor. For PMG-40, feed-zone temperatures of 45–50 °C and mixing-zone temperatures of 55–65 °C maintain melt viscosity low enough for distributive mixing. The practical processing window is ±5 °C around the mixing-zone set point because the solidification interval is sharp; excursions above 70 °C accelerate acid value drift and release free stearic acid, while excursions below 45 °C produce high-torque conditions and non-uniform granule formation. Screw speed and powder feed rate must be balanced to control specific mechanical energy input; when the melt floods the barrel, pressure fluctuations at the die face cause strand breakage on production-scale strand pelletizers.

High-shear wet granulation requires a separate binder preparation step. PMG is dissolved in purified water at 50–60 °C using a low-shear propeller mixer and cooled to 35–40 °C before spraying. Addition rate is adjusted to the granulator power-consumption curve; overwetting produces coarse granules and screen blinding during wet milling. Concentrations above 20% w/w in the binder solution may gel upon cooling and obstruct the spray nozzle, a common batch-scale failure mode in jacketed bowls. Moisture endpoint is set by loss on drying to 1–3% w/w, and granule size distribution is checked before tablet compression.

When Oxidative Stability of the Hydrophobic Tail Controls Finished-Product Shelf Life

The saturated C18 stearate chain of PMG-40 provides a measurable difference from polysorbate 80, whose C18:1 oleate chain contains a double bond. Polysorbate 80 can undergo autoxidation during storage, generating peroxides, aldehydes, and organic acids that degrade oxidation-sensitive actives. PMG removes this unsaturated-lipid route; the polyoxyethylene chain remains a potential source of peroxide, but the rate is lower under identical light and temperature stress. Peroxide value and acid value are monitored under ICH Q1A conditions of 40 °C and 75% relative humidity. Sorbitan monostearate shares the saturated C18 chain but has an HLB of approximately 4.7 and cannot provide clear aqueous solubilization without a co-surfactant. Sodium lauryl sulfate is anionic and can precipitate with cationic veterinary actives, whereas PMG is nonionic and retains surface activity across a broader pH range. Macrogol 15 hydroxystearate is a liquid paste with a branched hydrophobe and may be preferred for some injectable solubilizers, but PMG offers a defined crystalline solid for melt-based processes.

Analytical method compatibility is important because the waxy product must be melted before acid value, saponification value, and hydroxyl value tests. Titrations follow USP <401>; water content is determined by Karl Fischer titration according to USP <921>. Peroxide value should be measured by iodometric titration under inert atmosphere to avoid oxidation during sample preparation. Melting range is measured by USP <741>. HLB is estimated from the saponification value, but formulators may prefer direct surface tension measurement when substituting PMG for another nonionic surfactant. Analytical method transfer to a veterinary manufacturing site should include verification of the melting step, because overheating during sample preparation can produce falsely low ester values.

Oral solutions, drenches, and drinking-water concentrates are prepared from a heated stock solution of PMG-40 in purified water at 50–60 °C under low-shear propeller agitation. The stock can be diluted at room temperature because the cloud point of the 40-mole ethoxylate in purified water is generally above 100 °C; added electrolytes, preservatives, and high ionic-strength buffers may lower the cloud point and cause phase separation. Terminal steam sterilization at 121 °C should be followed by visual inspection and turbidity measurement because sub-micron surfactant aggregates can scatter light without visible precipitation.

Operational boundaries for the veterinary-grade product include ester hydrolysis at pH below 4 or above 8 at elevated temperature, moisture uptake at relative humidity above 60%, and thermal degradation above 70 °C. Store in sealed, light-resistant containers at or below 25 °C. Re-melt bulk material only under indirect heating and nitrogen, avoiding local hot spots above 70 °C. Avoid combination with strong oxidizing agents and with process streams containing high levels of free fatty acids, because acid value displacement can alter the monoester/diester balance and shift the melting range.